The Hong Kong Department of Health approved Abraxane (albumin-bound paclitaxel) for use in combination with gemcitabine as first-line treatment for patients with late-stage pancreatic cancer.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
